“Obviously there are advantages to developing orphan drugs, it’s attractive for private equity firms and pension funds to invest in them to get these treatments on the market.”
Evelyn Kelly, the founder of Orphan Drug Consulting, works in an industry fraught with difficult decisions. In this podcast, she talks to Rosanna Cooney about her company's role in bringing medicines to market as quickly as possible, the growth in the orphan drug market, and the challenges of equitable access to medication.
